← Back to Search

Exercise for Improved Walking After Stroke

N/A

Recruiting

Led By Darcy Reisman, PhD

Research Sponsored by University of Delaware

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18-85

Able to walk at self-selected speed without assistance from another person

Must not have

Inability to walk outside the home prior to the stroke

Coronary artery bypass graft or myocardial infarction within past 3 months

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 hours

Awards & highlights

No Placebo-Only Group

Summary

This trial will test if a new walking pattern can be learned by stroke patients through distorted visual feedback, and if this pattern can be retained without visual feedback immediately after learning and 24 hours later. Subjects will be randomly assigned to the control group or the exercise group. The control group will simply complete the learning task, while the exercise group will complete 5 minutes of exercise immediately following the first retention test.

Who is the study for?

This trial is for individuals aged 18-85 who have had a single, unilateral stroke more than 6 months ago and can walk unassisted. They must have a specific level of stroke severity, confirmed by MRI or CT scan, and normal heart rate and blood pressure. People with recent serious heart issues, walking-limiting pain, additional neurological conditions, or severe communication problems cannot join.

What is being tested?

The study examines how exercise affects the ability to retain a new walking pattern learned through visual feedback in chronic stroke survivors. Participants are divided into two groups: one does the learning task only (control), while the other performs exercises after learning to see if it helps memory retention after 24 hours.

What are the potential side effects?

Since this trial involves exercise as an intervention post-stroke rehabilitation therapy, potential side effects may include muscle soreness or fatigue due to physical activity. However, no significant adverse effects are expected from the described interventions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 85 years old.

Select...

I can walk on my own without help from others.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I couldn't walk outside my home before having a stroke.

Select...

I have not had a heart bypass or heart attack in the last 3 months.

Select...

I have pain in my muscles or bones that makes it hard to walk.

Select...

I have had a stroke in the cerebellum, confirmed by MRI or CT scan.

Select...

I have experienced unexplained dizziness in the past 6 months.

Select...

I have a neurological condition besides stroke.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

24 hour retention

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: ExerciseExperimental Treatment1 Intervention

Subjects will complete learning of a new walking pattern through distorted visual feedback and retention will be tested immediately without visual feedback. This will be followed immediately by 5 minutes of high intensity exercise. Retention without visual feedback will them be tested again 24 hours later.

Group II: ControlActive Control1 Intervention

Subjects will complete learning of a new walking pattern through distorted visual feedback and retention will be tested immediately after and 24 hours later (without visual feedback).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Exercise

2016

Completed Phase 1

~820

0 / 8Eligibility criteria met